DrugSniper, a Tool to Exploit Loss-Of-Function Screens, Identifies <i>CREBBP</i> as a Predictive Biomarker of VOLASERTIB in Small Cell Lung Carcinoma (SCLC)
The development of predictive biomarkers of response to targeted therapies is an unmet clinical need for many antitumoral agents. Recent genome-wide loss-of-function screens, such as RNA interference (RNAi) and CRISPR-Cas9 libraries, are an unprecedented resource to identify novel drug targets, repo...
Main Authors: | Fernando Carazo, Cristina Bértolo, Carlos Castilla, Xabier Cendoya, Lucía Campuzano, Diego Serrano, Marian Gimeno, Francisco J. Planes, Ruben Pio, Luis M. Montuenga, Angel Rubio |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/7/1824 |
Similar Items
-
Fusions involving BCOR and CREBBP are rare events in infiltrating glioma
by: David J. Pisapia, et al.
Published: (2020-06-01) -
Pathology and Classification of SCLC
by: Maria Gabriela Raso, et al.
Published: (2021-02-01) -
CNS tumor with CREBBP::BCORL1 Fusion and pathogenic mutations in BCOR and CREBBP: expanding the spectrum of BCOR-altered tumors
by: Valeria Barresi, et al.
Published: (2024-01-01) -
Mutation in the CREBBP Gene in the Girl with Toe Walking Syndrome: Clinical Case
by: David Pomarino, et al.
Published: (2021-10-01) -
Clinicopathological Difference and Survival Impact of Patients with c-SCLC and SCLC
by: Zhang C, et al.
Published: (2021-10-01)